The Technical Analyst
InspireMD Inc [NSPR]
Exchange: AMEX Industry: Medical Devices
InspireMD Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.82% $2.00
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 46.80 mill |
| EPS: | -0.820 |
| P/E: | -2.44 |
| Earnings Date: | May 14, 2024 |
| SharesOutstanding: | 23.40 mill |
| Avg Daily Volume: | 0.0347 mill |
| RATING 2024-04-26 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.44 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -2.44 | industry: PE 21.09 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.843 - 2.16 ( +/- 7.85%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-23 | Kester Thomas J | Buy | 29 032 | Common Stock |
| 2024-01-23 | Kester Thomas J | Buy | 11 098 | Options to purchase common stock (right to buy) |
| 2024-01-23 | Verta Patrick | Buy | 85 720 | Common Stock |
| 2024-01-23 | Verta Patrick | Buy | 32 768 | Options to purchase common stock (right to buy) |
| 2024-01-23 | Gleason Shane Thomas | Buy | 238 625 | Common Stock |
| INSIDER POWER |
|---|
| 98.06 |
| Last 99 transactions |
| Buy: 7 620 190 | Sell: 72 371 |
Forecast:
16:00 - $2.00
Live Trading Signals (every 1 min)
Forecast
1: 15:33 - $1.969
Forecast 2: 16:00 - $2.00
Forecast 3: 16:00 - $2.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.00 (5.82% ) |
| Volume | 0.0102 mill |
| Avg. Vol. | 0.0347 mill |
| % of Avg. Vol | 29.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NSPR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Latest Press Releases
2024-04-03 08:59:00 - Press Release
Inspiremd To Present At The 23rd Annual Needham Virtual Healthcare Conference
Tel aviv, israel and miami, april 03, 2024 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced that marvin slosman, chief executive officer, will deliver a company update presentation at the 23rd annual needham virtual healthcare conference, which is being held april 8-11, 2024.
2024-03-26 07:00:00 - Press Release
Inspiremd Announces Abstract Of One-year Follow-up Results From The c-guardians U.s. Investigational Device Exemption (ide) Clinical Trial Accepted For Presentation At Linc 2024
Tel aviv, israel and miami, march 26, 2024 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its c-guardians ide clinical trial of the cguard™ prime carotid stent system for the treatment of carotid artery stenosis has been accepted for presentation at the leipzig interventional course (linc) 2024, which is being held may 28-31, in leipzig, germany.
2024-03-06 07:00:00 - Press Release
Inspiremd Reports Fourth Quarter And Full-year 2023 Financial Results And Provides Business Update
- record fourth quarter 2023 cguard eps revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - announced positive 30-day data from the company's ongoing u.s. investigational device exemption (ide) clinical trial, c-guardians, designed to support u.s. approval of cguard prime - - named patrick geraghty, m.d. and patrick muck, m.d.
2024-02-28 07:00:00 - Press Release
Inspiremd To Report Fourth Quarter And Full-year 2023 Financial Results And Provide Corporate Business Update On Wednesday, March 6th
-conference call and webcast to be held at 8:30 a.m. est- tel aviv, israel and miami, feb. 28, 2024 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) device for the treatment of carotid artery disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on wednesday, march 6th, 2024, before the financial markets open.
2024-02-12 07:00:00 - Press Release
Inspiremd Appoints Principal Investigators For C-guardians Ii Clinical Trial Of The Switchguard™ Neuroprotection System
Development of switchguard™ consistent with company's mission to uniquely support both carotid artery stenting (cas) and transcarotid artery revascularization (tcar) procedures with best-in-class carotid implant and platform development of switchguard™ consistent with company's mission to uniquely support both carotid artery stenting (cas) and transcarotid artery revascularization (tcar) procedures with best-in-class carotid implant and platform
Latest News
2024-04-03 08:59:00 - GlobeNewsWire
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.
2024-02-28 07:00:00 - GlobeNewsWire
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open.
2024-02-05 12:31:05 - Zacks Investment Research
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.
2023-11-23 11:17:36 - Zacks Investment Research
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround
InspireMD, Inc. (NSPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2023-11-02 08:00:00 - GlobeNewsWire
InspireMD to Participate in Upcoming November Investor Conferences
TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:
2023-10-30 09:21:00 - GlobeNewsWire
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2023 financial results on Monday, November 6th, 2023, before the financial markets open.
2023-07-25 08:00:00 - GlobeNewsWire
InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2023 financial results on Tuesday, August 8thth, 2023, before the financial markets open.
2023-05-12 16:05:00 - GlobeNewsWire
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host its conference call and webcast to review first quarter 2023 financial and operating results on Tuesday, May 16th, 2023, before the markets open.
2023-03-02 08:00:00 - GlobeNewsWire
InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update
2022-11-08 12:56:04 - Seeking Alpha
InspireMD, Inc. (NSPR) Q3 2022 Earnings Call Transcript
InspireMD, Inc. (NASDAQ:NSPR ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.